Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
In conclusion, TMZ has potential for the treatment of highly aggressive and resistant prolactin-secreting adenomas and carcinomas, as demonstrated by tumor shrinkage or complete response and normalization of hormone hypersecretion, and exhibits good tolerability and few side effects.
PMID: 28742502 [PubMed - in process]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
More News: Cancer & Oncology | Carcinoma | Hormones | Oral Cancer | Pituitary Tumor | Study | Temodar